Exelixis, Inc. revenue for the last year amounted to 1.83 B USD, the most of which — 1.83 B USD — came from its highest performing source at the moment, Medicines for Difficult-to-treat Cancers, the year earlier bringing 1.61 B USD. The greatest contribution to the revenue figure was made by United States — last year it brought Exelixis, Inc. 1.65 B USD, and the year before that — 1.41 B USD.